WithdrawnPHASE1, PHASE2NCT05936229

Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy

Studying Acute lymphoblastic leukemia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Fred Hutchinson Cancer Center
Principal Investigator
Jordan Gauthier, PT. DPT
Fred Hutch/University of Washington Cancer Consortium
Intervention
Interferon Beta-1A(biological)
Eligibility
18 years · All sexes
Timeline
20252027

Study locations (1)

Collaborators

Faron Pharmaceuticals Ltd

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05936229 on ClinicalTrials.gov

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute lymphoblastic leukemia

← Back to all trials